CAPTaINs provide a novel, selective, and stable method for selective degradation of protein targets.

Researchers at the University of California, Davis have developed recombinant fusion protein compositions that inhibit pathological angiogenesis by targeting VEGF165-KDR interactions to treat cancers and related diseases.

Researchers at the University of California, Davis have developed methods that combine immunotherapeutic agents with dual inhibitors to enhance cancer treatment efficacy and prolong patient survival.

Researchers at the University of California, Davis have developed a peptide nucleic acid-based system enabling precise and customizable delivery of antigens, adjuvants, and targeting molecules for improved cancer immunotherapy.

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Researchers at the University of California, Davis have developed an innovative Cherenkov-based system for calibrating radiotherapy beams, enabling precise, real-time calibration of radiation dose delivery, including for high-intensity FLASH radiotherapy, improving treatment accuracy and reliability.

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Researchers at the University of California, Davis have developed a technology that introduces a TCTS (Two-component Two-step) drug delivery system designed to enhance cancer treatment efficacy while minimizing toxicity.

Researchers at the University of California, Davis have developed isolated peptides that selectively bind M1 and M2 macrophages to enable precise diagnosis and targeted treatment of macrophage-associated diseases, including cancer.

Researchers at the University of California, Davis have developed a nanoparticle system combining photothermal therapy and chemotherapy for enhanced cancer treatment.

Researchers at the University of California, Davis have developed a therapeutic approach to prevent and treat cancer cachexia by inhibiting soluble epoxide hydrolase, promoting resolution of systemic inflammation, mitigating muscle wasting, and improving survival outcomes in preclinical models without inducing toxicity or immunosuppression.

Brief description not available

Brief description not available